Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Somatostatinoma 2Carcinoma, Islet Cell 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymus Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Pheochromocytoma 1Pharyngeal Neoplasms 1Penile Neoplasms 1Parotid Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1

Interventions

lanreotide 1antineoplaston AS 2-1 1antineoplaston A10 1Temozolomide 1Surveys and Questionnaires 1Solutions 1Radiosurgery 1Observation 1Microarray Analysis 1Injections 1Early Intervention, Educational 1Diet, Mediterranean 1Diet, Ketogenic 1DNA Methylation 1Complementary Therapies 1Biological Therapy 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Growth Hormone-Secreting Pituitary Adenoma × Biological Therapy × Endocrine × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡